Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China 2020-10-09 19:14
Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period 2020-10-07 08:00
Innovent Biologics Announces to Host 2020 Virtual R&D Day on November 10th 2020-09-28 12:13
TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC) 2020-09-28 10:15
Innovent and Lilly Jointly Release Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with GEMZAR® (Gemcitabine) and Platinum Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020 2020-09-21 08:00
Innovent and Lilly Release Biomarker Results of TYVYT® (Sintilimab Injection) in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020 2020-09-21 08:00
Innovent and Lilly Jointly Announce Results of Six Clinical Studies of TYVYT® (sintilimab injection) to be Presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 2020-09-14 18:00
Innovent Announces NMPA Granted Marketing Approval for SULINNO® (Adalimumab Injection) in China 2020-09-03 17:50
Innovent Announces First Subject Dosed in the Phase 1 Clinical Trial of Anti-IL-23 Monoclonal Antibody 2020-09-01 08:00
Innovent Announces the Results of the Phase 1/2 Clinical Study of PCSK9 Antibody Tafolecimab at the European Society of Cardiology Annual Conference 2020-08-31 08:00
Innovent Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Progress 2020-08-27 09:37
Innovent and Lilly Announce Expansion of TYVYT® (Sintilimab Injection) Licensing Agreement 2020-08-18 18:30
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT® (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China 2020-08-12 16:40
Innovent and Lilly Release Clinical Trial Results of Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous NSCLC in an Oral Presentation at IASLC WCLC 2020 Virtual Presidential Symposium 2020-08-08 21:00
Innovent Announces First Patient Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody in China 2020-08-03 08:00
Innovent Announces First Patient Dosed in a Phase 1b Clinical Trial of Sintilimab plus Surufatinib in Advanced Malignancies in China 2020-07-09 08:00
Innovent Announces The Stock Exchange of Hong Kong Limited Approved the "B" Marker Removal from the Company's Stock Symbol in the HKEX 2020-06-22 07:40
Innovent Announces the NMPA Granted Marketing Approval for BYVASDA® (Bevacizumab Biosimilar) in China 2020-06-19 12:20
Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China 2020-06-18 12:00
Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies 2020-06-09 07:30
1 11 12 13 14 15 17